Diagnosis and treatment of polycystic ovary syndrome (PCOS): An interview with Richard Legro

BMC Medicine

Richard Legro¹ 

[1] Penn State University College of Medicine, H103, RM C3604, 500 University Drive, M.S. Hershey Medical Center, Hershey 17033, PA, USA

关键词: Endocrine;    Infertility;    Polycystic ovary syndrome;   

Others  :  1145221
DOI  :  10.1186/s12916-015-0299-2

 received in 2015-02-18, accepted in 2015-02-18,  发布年份 2015

【 摘 要 】

In this podcast, we talk to Professor Richard Legro about the recommendations for the diagnosis and treatment of polycystic ovary syndrome (PCOS) based on clinical practice guidelines and discuss the challenges of diagnosis PCOS at specific age groups. The controversies associated with treatment of PCOS, including therapies for infertility as this is a problem commonly observed in PCOS subjects, are highlighted together with future directions on the topic.

The podcast for this interview is available at. http://www.biomedcentral.com/content/supplementary/s12916-015-0299-2-s1.mp3 webcite

【 授权许可】

   
2015 Legro; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Legro RS, Driscoll D, Strauss JF, Fox J, Dunaif A: Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998, 95:14956-60.
• [2]Legro RS, Kunselman A, Dodson WC, Dunaif A: Prevalence and predictors for type 2 diabetes mellitus in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84:165-9.
• [3]Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP: Polycystic ovary syndrome is associated with obstructive sleep apnea and sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001, 86:517-20.
• [4]Sam S, Legro RS, Dunaif A: Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 2006, 103:7030-5.
• [5]Legro RS, Barnhart HX, Carson SA, Diamond MP, Carr BA, Schlaff WD, et al.: Clomiphene, metformin, or both for infertility in polycystic ovary syndrome. N Engl J Med 2007, 356:551-66.
• [6]Norman RJ, Dewailly D, Legro RS, Hickey TE: Polycystic ovary syndrome. Lancet 2007, 370:685-97.
• [7]Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali P, et al.: Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013, 98:4565-92.
• [8]Polotsky AJ, Allshouse A, Crawford SL, Harlow SD, Khalil N, Kazlauskaite R, et al.: Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. J Clin Endocrinol Metab 2014, 99:2120-7.
• [9]McAllister JM, Miller BA, Oshaben KK, Biegler J, Legro RS, Modi B, et al.: Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proc Natl Acad Sci U S A 2014, 111:E1519-27.
• [10]Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WE, Casson P, et al.: Effect of letrozole versus clomiphene in polycystic ovary syndrome. N Engl J Med 2014, 371:119-29.